All In Biotech

Drug Trial Radar · NCT06242470

A Study of MGC026 in Participants With Advanced Solid Tumors

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

394

Planned (sponsor's estimate)

Start

Mar 6, 2024

Primary completion

Oct 2028

Study completion Apr 2029

Sponsor

Lead sponsor
MacroGenicsIndustry
Sponsor type
Industry
First posted
Feb 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion. The dose of vobramitamab tavatecan will be assigned at the time of enrollment. Pembrolizumab will be administered at 200 mg every 3 weeks. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood and tumor samples collected for research purposes.

Conditions

  • Advanced Solid Tumor
  • Advanced Cancer
  • Metastatic Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Non Small Cell Lung Cancer
  • Small-cell Lung Cancer
  • Bladder Cancer
  • Sarcoma
  • Endometrial Cancer
  • Melanoma
  • Castration Resistant Prostatic Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Gastro-esophageal Cancer
  • Pancreas Cancer
  • Clear Cell Renal Cell Carcinoma
  • Hepatocellular Carcinoma
  • Platinum-resistant Ovarian Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Esophageal Squamous Cell Cancer (SCC)

Interventions

  • MGC026 Dose EscalationBiological

    Escalating doses of MGC026

  • MGC026 Dose for ExpansionBiological

    MGC026 recommended dose for expansion

  • PembrollizumabBiological

    200 mg, IV, every 3 weeks.

  • vobramitamab tavatecanBiological

    less than RDE dose level, IV, every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest.Time frame: Throughout the study, up to 135 weeks

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute

    Los Angeles, California · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • START-New York Long Island

    Lake Success, New York · Recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • ICON Cancer Centre Wesley

    Auchenflower, Queensland, Australia · Recruiting

  • ICON Cancer Centre Kurralta Park

    Kurralta Park, South Australia, Australia · Recruiting

  • Austin Health- Olivia Newton John Cancer Center

    Heidelberg, Victoria, Australia · Recruiting

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom · Recruiting

  • The Royal Marsden NHS Foundation Trust

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.